DENVER and CAMBRIDGE, Mass., April 14 /PRNewswire/ -- (AACR 100th Annual Meeting 2009) - Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that the results of a joint collaboration with one of its top pharmaceutical partners will be presented at the American Association for Cancer Research's (AACR) 100th Annual Meeting 2009 being held in Denver, Colo. April 18-22, 2009.
Michael Macoritto, Ph.D., project lead/scientist II at Genstruct will be presenting a poster titled, "Causal Reasoning Identifies Mechanisms of Sensitivity for a Novel AKT Kinase Inhibitor: GSK690693" on April 21 from 1:00 - 5:00 p.m. The poster will focus on how Genstruct and its partner evaluated the mechanisms for sensitivity for GSK690693 in six cell cultures and three xenografts from human breast, prostate and ovarian cancer cell lines using Genstruct's Causal Network(TM) modeling platform on RNA expression and phosphoproteomics data.
"This research project is an excellent example of the capabilities of our Causal Network Modeling platform," said Dr. Macoritto. "By using causal modeling, our team of expert scientists was able to demonstrate one of the main tenets of systems biology -- that the networks that regulate cellular processes are conserved across tumor and tissue types, even when the transcriptional responses of these tissues are markedly different."
Founded in 2002, Genstruct is a systems biology company focused on elucidating the complexity of biology for the development of safe a
Copyright©2009 PR Newswire.
All rights reserved